SecBot SecBot

HOWL

Werewolf Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001785530 Biotech & Drug Discovery
$0.9810 +0.00 (+0.10%)
Oct 26 4:00 PM ET · prev $0.9800
Market cap
$49.1M
Nano cap
Median target
$7.00
+614% · range $4.00–10.00
Next earnings
Nov 2
in 7 days · EPS est. −$0.22
1 year
−42.0%
from $1.69 · Oct 27
30 days
+5.5%
from $0.9300
52-week range
$0.3080–1.69
−42% from high · low Jun 29
Avg volume 20D
465.0K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$2.0M
0 buyers · 2 sellers · since Apr 29
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
24
analyzed by SecBot
SecBot read BEARISH 8 reports · 90 days
Balance 3 bearish · 2 bullish · 2 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 6/8 ·Next Earnings date, Nov 2, 2026
Strongest BEARISH Werewolf Therapeutics (HOWL) filed an S-4 registration statement for its merger with Ambros Therapeutics…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $2.0M.

  • InstitutionsMIXED

    Q2 2026: 3 added (0 new), 5 trimmed or exited.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.220 → −$0.220 over 90 days. 1 up, 0 down in 30 days.

  • TrendUPTREND

    7% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
RA CAPITAL MANAGEMENT, L.P.TRIM2,387,744$859.3K
RENAISSANCE TECHNOLOGIES LLCADD674,632$242.8K
JANE STREET GROUP, LLCDOUBLED251,837$90.6K
UBS Group AGDOUBLED215,838$77.7K
MILLENNIUM MANAGEMENT LLCTRIM62,055$22.3K
GOLDMAN SACHS GROUP INCTRIM20,023$7.2K
MORGAN STANLEYTRIM19,108$6.9K
SIMPLEX TRADING, LLCNEAR_EXIT255$91.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Dec 2025
12-month targets · 3 analysts

Price is below the lowest target. Median implies +614%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Dec 19, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Nov 18, 2025B of A Securities
MAINTAIN
MAINTAINBuy
Aug 25, 2025B of A Securities
MAINTAIN
MAINTAINBuy
Aug 21, 2025JMP Securities
MAINTAIN
MAINTAINMarket Outperform
May 9, 2025Wedbush
MAINTAIN
MAINTAINOutperform
Mar 12, 2025Wedbush
REITERATE
REITERATEOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$2.0M
sold · 2 insiders
DateInsiderTypeValue
Jul 7, 2026
EVNIN LUKE
Director
SELL$33.3K
Jul 6, 2026
EVNIN LUKE
Director
SELL$11.4K
Jun 29, 2026
EVNIN LUKE
Director
SELL$47.1K
Jun 17, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
SELL$136.2K
Jun 17, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
SELL$9.7K
Jun 16, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
SELL$51.7K
Jun 16, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
SELL$3.7K
Jun 15, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
SELL$46.9K

Earnings setup

Estimates
Nov 2
reports in 7 days
−$0.22
EPS estimate, this quarter
0%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.22-$0.22–-$0.22+31.3%$0.00
Next Q-$0.17-$0.17–-$0.17—$0.00
Current FY-$0.89-$0.89–-$0.89+29.9%$0.00
Next FY-$0.59-$0.59–-$0.59—$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Aug 21, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Sep 30, 2026 Short interest report
Short Interest: HOWL up 47% to 2.5M shares
Settlement 2026-09-30 | Days to cover: 3.70 | ≈5.17% of shares outstanding (est.)
Sep 22, 2026 SEC
Werewolf Therapeutics (HOWL) filed an S-4 registration statement for its merger with Ambros Therapeutics, where Ambros…
S-4 — Impact 7/10
Sep 21, 2026 SEC
Peter Moll, a private investor based in Dresden, Germany, disclosed a 5.2% passive stake in Werewolf Therapeutics via…
SC 13G — Impact 3/10
Aug 21, 2026 Press
Werewolf Therapeutics (HOWL) announced a definitive all-stock merger with Ambros Therapeutics, valuing Ambros at $500M…
Impact 7/10
Jul 7, 2026 Insider
EVNIN LUKE sold 107,429 shares
Director @ $0.3100 ($33.3K)
Jul 6, 2026 Insider
EVNIN LUKE sold 35,770 shares
Director @ $0.3200 ($11.4K)
Jun 30, 2026 Inst.
RA CAPITAL MANAGEMENT, L.P. — TRIM
2,387,744 shares ($859.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 2, 2026
Earnings date
HOWL Q3 2026 Earnings Scheduled — 2026-11-02
Recent
Oct 19, 2026
Clinical Trial
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
Phase 2 · COMPLETED
Sep 30, 2026
Short interest
Short Interest: HOWL up 47% to 2.5M shares
Settlement 2026-09-30 | Days to cover: 3.70 | ≈5.17% of shares outstanding (est.)
Aug 31, 2026
Short interest
Short Interest: HOWL up 56% to 1.7M shares
Settlement 2026-08-31 | Days to cover: 1.00 | ≈3.43% of shares outstanding (est.)
Aug 21, 2026
Trading halt
Halt Resumed: HOWL — trading resumed after T3 (News and Resumption Times)
Halted 2026-08-21T11:55:00.000Z | Resumed 2026-08-21T12:20:00.000Z
Aug 21, 2026
M&A
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today…

SecBot reports

24 filings · 1 press release · 2 bullish · 13 bearish · 2 mixed · 7 neutral
All HOWL filing & press-release reports (25)